Skip to main content

Advertisement

SpringerLink
Log in

An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Oral administration of cyclophosphamide (CTX) and capecitabine may have a greater potential for treatment of metastatic breast cancer (MBC) due to anti-angiogenesis resulting from the metronomic dosage and upregulation of thymidine phosphorylase by CTX. The purpose of this phase II study was to evaluate the efficacy and safety profile of an all-oral combination of metronomic CTX plus capecitabine for women with anthracycline- and taxane-pretreated MBC.

Method

In this prospective single-center, open-label, phase II trial, patients with measurable disease received oral metronomic CTX 65 mg/m2 daily on days 1–14 plus capecitabine 1,000 mg/m2 twice daily on days 1–14. The treatment was repeated every 3 weeks, and continued until disease progression, unacceptable toxicity or withdrawal of informed consent. The primary endpoint of the study was time to progression (TTP).

Results

A total of 68 patients were enrolled and received 537 cycles of chemotherapy with a median of 8 cycles (range: 1–30 cycles) per patient. Sixty-six patients were evaluated for efficacy with all patients for toxicity. With a median follow-up time of 26 months, the median time to progression was 5.2 months (95% CI, 4.2–6.2 months), and the median overall survival was 16.9 months. The overall response rate was 30.3% (95% CI, 20–43%). Clinical benefit rate was 53.0% (95% CI, 38–62%). The doublet was well tolerable, with anorexia (7.5%), the only grade 3/4 adverse events occurring in more than 5% of patients. Grade 3 hand–foot syndrome was 4.4%.

Conclusion

The all-oral combination of metronomic CTX plus capecitabine is an effective and convenient and well-tolerated regimen for MBC. (ClinicalTrials.gov number, NCT00589901).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Perez EA (2009) Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer. Breast Cancer Res Treat 114:195–201

    Article  PubMed  CAS  Google Scholar 

  2. Giordano SH, Buzdar AU, Smith TL et al (2004) Is breast cancer survival improving? Cancer 100:44–52

    Article  PubMed  Google Scholar 

  3. Engelsman E, Klijn JC, Rubens RD et al (1991) “Classical” CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808). Eur J Cancer 27:966–970

    Article  PubMed  CAS  Google Scholar 

  4. Blum JL, Jones SE, Buzdar AU et al (1999) Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17:485–493

    PubMed  CAS  Google Scholar 

  5. Blum JL, Dieras V, Lo Russo PM et al (2001) Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 92:1759–1768

    Article  PubMed  CAS  Google Scholar 

  6. Reichardt P, Von Minckwitz G, Thuss-Patience PC et al (2003) Multicenter phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 14:1227–1233

    Article  PubMed  CAS  Google Scholar 

  7. Fumoleau P, Largillier R, Clippe C et al (2004) Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 40:536–542

    Article  PubMed  CAS  Google Scholar 

  8. Wist EA, Sommer HH, Ostenstad B et al (2004) Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer. Acta Oncol 43:186–189

    Article  PubMed  Google Scholar 

  9. Thomas ES, Gomez HL, Li RK et al (2007) Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 25:5210–5217

    Article  PubMed  CAS  Google Scholar 

  10. Estévez LG, Batista N, Sánchez-Rovira P et al (2008) A phase II study of capecitabine and vinorelbine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes. Clin Breast Cancer 8:149–154

    Article  PubMed  Google Scholar 

  11. Orphanos G, Alexopoulos A, Malliou S et al (2010) A phase II trial of the combination of vinorelbine and capecitabine as second-line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines. J Cancer Res Clin Oncol 136:115–121

    Article  PubMed  CAS  Google Scholar 

  12. Ahn JH, Kim SB, Kim TW et al (2004) Capecitabine and vinorelbine in patients with metastatic breast cancer previously treated with anthracycline and taxane. J Korean Med Sci 19:547–553

    Article  PubMed  CAS  Google Scholar 

  13. Jones A, O’Brien M, Sommer H et al (2010) Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes. Cancer Chemother Pharmacol 65:755–763

    Article  PubMed  CAS  Google Scholar 

  14. Andres R, Mayordomo JI, Lara R et al (2005) Gemcitabine/capecitabine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes. Clin Breast Cancer 6:158–162

    Article  PubMed  CAS  Google Scholar 

  15. Benekli M, Yildiz R, Uner A et al (2007) Gemcitabine plus capecitabine combination in metastatic breast cancer patients previously treated with anthracyclines and taxanes. Oncology 72:308–313

    Article  PubMed  CAS  Google Scholar 

  16. Malmström A, Hansen J, Malmberg L et al (2010) Gemcitabine and capecitabine in combination for advanced anthracycline and taxane pre-treated breast cancer patients: a phase II study. Acta Oncol 49:35–41

    Article  PubMed  Google Scholar 

  17. Maisano R, Caristi N, Mare M et al (2007) Mitomycin C plus capecitabine (mixe) in anthracycline- and taxane-pretreated metastatic breast cancer. A multicenter phase II study. Anticancer Res 27:2871–2875

    PubMed  CAS  Google Scholar 

  18. Massacesi C, La Cesa A, Marcucci F et al (2006) Capecitabine and mitomycin C is an effective combination for anthracycline- and taxane-resistant metastatic breast cancer. Oncology 70:294–300

    Article  PubMed  CAS  Google Scholar 

  19. Oksuzoglu B, Abali H, Hayran M et al (2008) Capecitabine and cisplatin combination is an active and well-tolerated doublet in the treatment of metastatic breast carcinoma patients pretreated with anthracycline and taxanes. Chemotherapy 54:352–356

    Article  PubMed  CAS  Google Scholar 

  20. Donadio M, Ardine M, Berruti A et al (2005) Weekly cisplatin plus capecitabine in metastatic breast cancer patients heavily pretreated with both anthracycline and taxanes. Oncology 69:408–413

    Article  PubMed  CAS  Google Scholar 

  21. Polyzos A, Gogas H, Markopoulos C et al (2009) Salvage chemotherapy with oxaliplatin and capecitabine for breast cancer patients pretreated with anthracyclines and taxanes. Anticancer Res 29:2851–2856

    PubMed  CAS  Google Scholar 

  22. Schmid P, Kühnhardt D, Kiewe P et al (2008) A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. Ann Oncol 19:871–876

    Article  PubMed  CAS  Google Scholar 

  23. Schaller G, Fuchs I, Gonsch T et al (2007) Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes. J Clin Oncol 25:3246–3250

    Article  PubMed  CAS  Google Scholar 

  24. Ishida T, Kiba T, Takeda M et al (2009) Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes. Cancer Chemother Pharmacol 64:361–369

    Article  PubMed  CAS  Google Scholar 

  25. Bottini A, Generali D, Brizzi MP et al (2006) Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J Clin Oncol 24:3623–3628

    Article  PubMed  CAS  Google Scholar 

  26. Colleoni M, Orlando L, Sanna G et al (2006) Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol 17:232–238

    Article  PubMed  CAS  Google Scholar 

  27. Loven D, Be’ery E, Yerushalmi R et al (2008) Daily low-dose/continuous capecitabine combined with neo-adjuvant irradiation reduces VEGF and PDGF-BB levels in rectal carcinoma patients. Acta Oncol 47:104–109

    Article  PubMed  CAS  Google Scholar 

  28. Sawada N, Ishikawa T, Fukase Y et al (1998) Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 4:1013–1019

    PubMed  CAS  Google Scholar 

  29. Endo M, Shinbori N, Fukase Y et al (1999) Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5’-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models. Int J Cancer 83:127–134

    Article  PubMed  CAS  Google Scholar 

  30. O’Shaughnessy J, Miles D, Vukelja S et al (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20:2812–2823

    Article  PubMed  Google Scholar 

  31. Lueck H, Minckwitz GV, Bois AD et al. (2006) Epirubicin/paclitaxel (EP) vs. capecitabine/paclitaxel (XP) in first-line metastatic breast cancer (MBC): a prospective, randomized multicentre phase III study of the AGO breast cancer study group. J Clin Oncol 24:18 s

    Google Scholar 

  32. Ohno S, Mitsuyama S, Tamura K et al (2007) Dosage of capecitabine and cyclophosphamide combination therapy in patients with metastatic breast cancer. Anticancer Res 27:1009–1013

    PubMed  CAS  Google Scholar 

  33. Hennessy BT, Gauthier AM, Michaud LB et al (2005) Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer. Ann Oncol 16:1289–1296

    Article  PubMed  CAS  Google Scholar 

  34. Liu G, Franssen E, Fitch MI et al (1997) Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15:110–115

    PubMed  CAS  Google Scholar 

  35. Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733–2743

    Article  PubMed  CAS  Google Scholar 

  36. Miller KD, Chap LI, Holmes FA et al (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792–799

    Article  PubMed  CAS  Google Scholar 

  37. von Minckwitz G, du Bois A, Schmidt M et al (2009) Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03–05 study. J Clin Oncol 27:1999–2006

    Article  Google Scholar 

  38. Robert NJ, Dieras V, Glaspy J et al (2011) RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29:1252–1260

    Article  PubMed  CAS  Google Scholar 

  39. Brufsky A, Bondarenko IN, Smirnov V et al (2009) RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trialevaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer. Cancer Res 69(24 Supplement):42

    Article  Google Scholar 

  40. Tanaka M, Takamatsu Y, Anan K et al (2010) Oral combination chemotherapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: a phase II study. Anticancer Drugs 21:453–458

    Article  PubMed  CAS  Google Scholar 

  41. Tong DK, Cheng CW, Ching Chan S et al (2005) Phase II study of an ‘all-oral’ regimen of capecitabine, idarubicin and cyclophosphamide for metastatic breast cancer—safety, efficacy and quality of life. Oncology 68:520–525

    Article  PubMed  CAS  Google Scholar 

  42. Schott AF, Lew D, Barlow WE et al (2010) Simple oral therapy with capecitabine (CAPE) and cyclophosphamide (CPA) for metastatic breast cancer (MBC). J Clin Oncol 28:15s

    Google Scholar 

  43. Haller DG, Cassidy J, Clarke S et al (2006) Tolerability of fluoropyrimidines appears to differ by region. J Clin Oncol 24:18s

    Article  Google Scholar 

  44. Bonadonna G, Brusamolino E, Valagussa P et al (1976) Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294:405–410

    Article  PubMed  CAS  Google Scholar 

  45. Levine MN, Bramwell VH, Pritchard KI et al (1998) Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 16:2651–2658

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported by the Foundation of young backbone start-up fund of Fudan University Cancer Hospital, PR China, contract No.GG200602.

Conflict of interest

The author(s) declare that they have no competing interests.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Cancer Hospital of Fudan University, Shanghai Medical College, 270 Dongan Road, Shanghai, 200032, China

    Zhonghua Wang, Shiangjiin Leaw, Xiaonan Hong, Jialei Wang & Xichun Hu

  2. Department of Breast Surgery, Cancer Hospital of Fudan University, Shanghai Medical College, Shanghai, China

    Jingsong Lu & Zhimin Shao

Authors
  1. Zhonghua Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jingsong Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shiangjiin Leaw
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiaonan Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jialei Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zhimin Shao
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xichun Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xichun Hu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, Z., Lu, J., Leaw, S. et al. An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study. Cancer Chemother Pharmacol 69, 515–522 (2012). https://doi.org/10.1007/s00280-011-1728-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-011-1728-3

Keywords

Search

Navigation